In patients with ACS on dual antiplatelet therapy, spontaneous major bleeding events seem prognostically equivalent to spontaneous ischemic complications.
In patients with ACS on dual antiplatelet therapy, spontaneous major bleeding events seem “prognostically equivalent” to spontaneous ischemic complications.
Evaluation of antithrombotic treatments for acute coronary syndromes (ACS) requires balancing ischemic and bleeding risks to assess net benefit. We sought to ...
An analysis of the PLATO trial found that spontaneous major bleeding events were associated with similar mortality rates (short and long term) as spontaneous ...
People also ask
How can you reduce the risk of acute coronary syndrome?
What is the protocol for ACS management?
Which findings on a 12 lead ECG would be expected in a patient with high risk non-ST segment elevation (acute coronary syndromes (NSTE ACS)?
What is an acute ischemic coronary event?
Dive into the research topics of 'Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes'. Together they form a unique ...
Jul 19, 2022 · In this study we provide direct comparison between the risks of further ischaemic events and bleeding events in patients who have survived 6 ...
In patients with ACS on dual antiplatelet therapy, spontaneous major bleeding events seem “prognostically equivalent” to spontaneous ischemic complications.
Use of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the key for the prevention of ischemic complications in patients with acute ...
Missing: spontaneous | Show results with:spontaneous
Jul 19, 2022 · Acute coronary syndrome Bleeding risk Recurrent ischaemic risk. *Corresponding author at: Department of Cardiology, Concord Hospital, Concord ...
Evaluation of antithrombotic treatments for acute coronary syndromes (ACS) requires balancing ischemic and bleeding risks to assess net benefit.